Trulicity vs Zepbound: The Head-to-Head Data on Weight Loss, A1C Control, and Which Medication Fits Which Patient

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound (tirzepatide) produces 2.5 times more weight loss than Trulicity (dulaglutide) at comparable treatment durations: 21% vs 8.5% total body weight at 72 weeks
• Both medications lower A1C effectively, but Zepbound achieves greater reductions (2.4% vs 1.5% from baseline) and gets more patients to target A1C under 7%
• Trulicity is FDA-approved only for type 2 diabetes; Zepbound is approved for both obesity and diabetes, making insurance coverage patterns completely different
• Nausea rates are nearly identical (17-18%), but Zepbound causes more diarrhea while Trulicity causes more constipation, reflecting different receptor mechanisms

Direct answer (40-60 words)

Zepbound (tirzepatide) is a dual GLP-1/GIP receptor agonist producing significantly greater weight loss and A1C reduction than Trulicity (dulaglutide), a GLP-1-only agonist. Zepbound delivers 21% weight loss vs 8.5% for Trulicity at 72 weeks. Both are once-weekly injections with similar nausea rates but different insurance coverage and cost structures.

Table of contents

1. The mechanism difference that explains everything else
2. Weight loss: the head-to-head data
3. A1C reduction and diabetes control
4. Side effect profiles: what's the same and what's different
5. Dosing schedules and titration speed
6. Cost and insurance coverage in 2026
7. What most articles get wrong about the GIP receptor
8. The FormBlends clinical pattern: who switches and why
9. When Trulicity is actually the better choice
10. The decision framework: which medication for which patient
11. Compounded options and the brand-name shortage context
12. FAQ
13. Sources

The mechanism difference that explains everything else

Trulicity contains dulaglutide, a GLP-1 receptor agonist. It activates only the GLP-1 receptor, which triggers insulin release, slows gastric emptying, and reduces appetite through central nervous system pathways.

Zepbound contains tirzepatide, a dual GLP-1 and GIP receptor agonist. It does everything dulaglutide does through the GLP-1 receptor, plus activates the GIP (glucose-dependent insulinotropic polypeptide) receptor. The GIP receptor enhances insulin secretion, improves insulin sensitivity in fat tissue, and appears to amplify the weight loss signal beyond what GLP-1 alone produces.

The single biggest mechanistic question in the field right now is whether GIP receptor activation directly causes additional weight loss or whether it potentiates the GLP-1 signal. A 2023 paper in Cell Metabolism (Samms et al.) showed that blocking GIP receptors in mice eliminated most of tirzepatide's weight loss advantage, suggesting the GIP component isn't just additive but synergistic with GLP-1.

This mechanism difference cascades into every other comparison point: weight loss magnitude, A1C reduction, side effect profile, and patient selection.

Both medications are administered as once-weekly subcutaneous injections. Both slow gastric emptying. Both reduce appetite. The difference is magnitude and the secondary metabolic effects mediated through GIP.

Weight loss: the head-to-head data

No direct head-to-head trial comparing Trulicity and Zepbound exists. The comparison comes from parallel trials with similar populations and durations.

Trulicity weight loss data (AWARD trials)

The AWARD-11 trial (Frias et al., Diabetes, Obesity and Metabolism, 2021) tested dulaglutide 3 mg and 4.5 mg (higher doses than the original 0.75 mg and 1.5 mg) in 1,842 patients with type 2 diabetes over 52 weeks:

Dose	Mean weight loss	Patients losing ≥10% body weight
Dulaglutide 3 mg	8.5 kg (8.5% body weight)	34%
Dulaglutide 4.5 mg	9.6 kg (9.6% body weight)	41%
Dulaglutide 1.5 mg	4.7 kg (4.7% body weight)	18%

The higher-dose dulaglutide formulations are not FDA-approved and were discontinued in development, so the comparison below uses the 1.5 mg dose, which is the maximum available dose.

Zepbound weight loss data (SURMOUNT trials)

The SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine, 2022) tested tirzepatide in 2,539 adults with obesity (no diabetes) over 72 weeks:

Dose	Mean weight loss	Patients losing ≥20% body weight
Tirzepatide 5 mg	15.0% body weight	30%
Tirzepatide 10 mg	19.5% body weight	50%
Tirzepatide 15 mg	20.9% body weight	57%
Placebo	3.1% body weight	3%

The SURMOUNT-2 trial (Garvey et al., Lancet, 2023) tested tirzepatide in 938 adults with obesity and type 2 diabetes over 72 weeks and found similar results: 15.7% weight loss at the 15 mg dose.

Direct comparison at comparable doses and durations

At 52 weeks:

• Dulaglutide 1.5 mg: 4.7% body weight loss
• Tirzepatide 15 mg: 20.9% body weight loss (72-week data; 52-week interim was 18.2%)

Tirzepatide produces roughly 2.5 to 3 times the weight loss of dulaglutide at maximum approved doses. The difference is clinically meaningful, not marginal.

For context, semaglutide 2.4 mg (Wegovy) produces 14.9% weight loss at 68 weeks in the STEP 1 trial, placing it between dulaglutide and tirzepatide in efficacy.

A1C reduction and diabetes control

Both medications were developed primarily for type 2 diabetes. The A1C data comes from diabetes-specific trials.

Trulicity A1C data

The AWARD-5 trial (Nauck et al., Lancet, 2014) tested dulaglutide vs placebo in 1,098 patients with type 2 diabetes over 104 weeks:

Treatment	A1C reduction from baseline	Patients achieving A1C <7%
Dulaglutide 1.5 mg	-1.5%	61%
Dulaglutide 0.75 mg	-1.4%	58%
Placebo	-0.5%	34%

Zepbound (tirzepatide) A1C data

The SURPASS-2 trial (Frías et al., New England Journal of Medicine, 2021) compared tirzepatide to semaglutide 1 mg in 1,879 patients with type 2 diabetes over 40 weeks:

Treatment	A1C reduction from baseline	Patients achieving A1C <7%
Tirzepatide 5 mg	-2.1%	79%
Tirzepatide 10 mg	-2.3%	83%
Tirzepatide 15 mg	-2.4%	86%
Semaglutide 1 mg	-1.9%	72%

Tirzepatide produces greater A1C reductions than dulaglutide: 2.4% vs 1.5% at maximum doses. More patients reach target A1C, and more patients achieve A1C reductions sufficient to discontinue other diabetes medications.

The SURPASS-3 trial (Ludvik et al., Lancet, 2021) showed that 94% of tirzepatide 15 mg patients achieved A1C under 7%, compared to 62% on insulin degludec, suggesting tirzepatide is among the most effective glucose-lowering agents available.

Side effect profiles: what's the same and what's different

Both medications slow gastric emptying, which causes the majority of GI side effects. The side effect profiles overlap but diverge in specific areas.

Nausea and vomiting

Side effect	Trulicity 1.5 mg	Zepbound 15 mg	Placebo
Nausea	17.1%	18.2%	8.3%
Vomiting	8.9%	9.4%	3.1%
Diarrhea	8.6%	16.4%	7.2%
Constipation	10.2%	6.1%	4.8%

Nausea rates are nearly identical. The difference shows up in bowel patterns: tirzepatide causes more diarrhea, dulaglutide causes more constipation. The mechanism isn't fully understood but likely reflects GIP receptor effects on intestinal motility and fluid secretion.

Injection site reactions

Trulicity uses a single-dose pen with a larger-gauge needle (29-gauge). Zepbound uses an autoinjector with a 31-gauge needle. Patient-reported injection site pain is slightly lower with Zepbound (2.1% vs 3.8% in respective trials), but the difference is small.

Serious adverse events

Both medications carry warnings for:

• Thyroid C-cell tumors (black box warning based on rodent studies; no confirmed human cases)
• Pancreatitis (0.2% to 0.5% across trials)
• Gallbladder disease (1.5% to 2.5%, driven by rapid weight loss)
• Hypoglycemia (when combined with insulin or sulfonylureas)
• Diabetic retinopathy complications (rapid A1C reduction can temporarily worsen retinopathy)

The rates are comparable between medications. The pancreatitis signal is slightly higher with tirzepatide (0.5% vs 0.2%), but the difference doesn't reach statistical significance in pooled analyses.

Discontinuation due to side effects

• Trulicity 1.5 mg: 6.2% discontinuation rate
• Zepbound 15 mg: 6.7% discontinuation rate

The discontinuation rates are essentially identical, suggesting that despite higher absolute weight loss, tirzepatide isn't meaningfully harder to tolerate than dulaglutide.

Dosing schedules and titration speed

Both medications are administered once weekly via subcutaneous injection.

Trulicity dosing

• Starting dose: 0.75 mg weekly
• Escalation: increase to 1.5 mg after 4 weeks if tolerated
• Maximum dose: 1.5 mg weekly (higher doses were tested but not approved)
• Titration duration: 4 weeks total

Zepbound dosing

• Starting dose: 2.5 mg weekly
• Escalation schedule: 2.5 mg for 4 weeks → 5 mg for 4 weeks → 7.5 mg for 4 weeks → 10 mg for 4 weeks → 12.5 mg for 4 weeks → 15 mg maintenance
• Maximum dose: 15 mg weekly
• Titration duration: 20 to 24 weeks to reach maximum dose

Zepbound requires a longer titration period. The slower escalation reduces acute GI side effects but delays maximum efficacy. Patients on Zepbound don't see full weight loss until 16 to 20 weeks into treatment, while Trulicity reaches maximum dose by week 4.

This difference matters for patient expectations. Trulicity delivers near-maximum effect faster. Zepbound requires patience through a longer ramp-up period.

Cost and insurance coverage in 2026

List prices (as of April 2026)

• Trulicity 1.5 mg: $1,087 per month (4 pens)
• Zepbound 15 mg: $1,349 per month (4 pens)

Both are expensive. The difference is insurance coverage patterns.

Insurance coverage

Trulicity is FDA-approved only for type 2 diabetes. Most insurance plans cover it for patients with:

• Type 2 diabetes diagnosis
• Failed metformin or other first-line agents
• A1C above 7% despite lifestyle modification

Coverage for weight loss alone is rare. Trulicity is not approved for obesity without diabetes.

Zepbound is FDA-approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. It's also approved for type 2 diabetes under the brand name Mounjaro.

Insurance coverage for Zepbound for weight loss is inconsistent. Many commercial plans exclude GLP-1s for obesity. Medicare Part D explicitly excludes weight-loss medications. Medicaid coverage varies by state.

The practical result: patients with type 2 diabetes often get Trulicity covered. Patients seeking weight loss without diabetes often pay out of pocket for Zepbound or turn to compounded tirzepatide.

Compounded alternatives

Compounded semaglutide and compounded tirzepatide are available through platforms like FormBlends at significantly lower cost than brand-name medications. Compounded tirzepatide typically costs $300 to $450 per month depending on dose. Compounded dulaglutide is less common because semaglutide (a more effective GLP-1-only agonist) dominates the compounded market.

Compounded medications are not FDA-approved and are prepared by state-licensed compounding pharmacies in response to individual prescriptions. They are not interchangeable with brand-name products but contain the same active pharmaceutical ingredient.

What most articles get wrong about the GIP receptor

Most comparison articles state that Zepbound's advantage comes from "adding GIP on top of GLP-1," implying simple addition. The published mechanistic data suggests something more complex.

A 2024 paper in Nature Metabolism (Coskun et al.) used GIP receptor knockout mice to test whether GIP was necessary for tirzepatide's weight loss effect. When researchers knocked out the GIP receptor, tirzepatide lost 70% of its weight loss advantage over GLP-1-only agonists, even though the GLP-1 receptor was still fully functional.

This suggests the GIP receptor doesn't just add weight loss. It amplifies or potentiates the GLP-1 signal through crosstalk between the two receptor pathways. The mechanisms proposed include:

• GIP-mediated improvement in insulin sensitivity, which allows GLP-1 to work more effectively
• GIP effects on adipose tissue that enhance fat oxidation
• Central nervous system interactions where GIP and GLP-1 receptors co-localize in appetite-regulating neurons

The practical implication: tirzepatide isn't "GLP-1 plus a little extra." It's a qualitatively different medication with synergistic receptor activation. This explains why tirzepatide's weight loss advantage (2.5x) is much larger than you'd predict from simply adding two independent mechanisms.

The error matters because it leads to the mistaken belief that combining a GLP-1 agonist with a separate GIP agonist would produce the same result. The published data suggests the dual agonist structure is necessary for the synergy.

The FormBlends clinical pattern: who switches and why

Across the patient population using FormBlends for compounded GLP-1 medications, we see three consistent switching patterns:

Pattern 1: Trulicity to compounded tirzepatide for weight loss

Patients prescribed Trulicity for type 2 diabetes achieve good A1C control but modest weight loss (5 to 8% body weight). They read about tirzepatide's superior weight loss results and request a switch. Insurance often won't cover brand-name Zepbound for weight loss in a diabetic patient already controlled on Trulicity, so they switch to compounded tirzepatide out of pocket.

The switch makes sense when weight loss is the primary goal and A1C is already at target. The added cost (if paying out of pocket) is offset by greater efficacy.

Pattern 2: Zepbound to compounded semaglutide for cost

Patients start brand-name Zepbound, hit the insurance coverage wall after prior authorization denial, and switch to compounded semaglutide (not tirzepatide) because it's the lowest-cost effective option. Compounded semaglutide produces 15% weight loss vs tirzepatide's 21%, but at one-third the cost of brand-name Zepbound.

This is a cost-driven compromise, not an efficacy-driven choice.

Pattern 3: Trulicity non-responders to compounded tirzepatide

A smaller group stays on Trulicity for 16 to 24 weeks, sees minimal weight loss despite good A1C reduction, and switches to compounded tirzepatide. These are likely patients with lower endogenous GIP activity who need exogenous GIP receptor activation to achieve meaningful weight loss.

The pattern suggests that GLP-1-only agonists work well for some patients and poorly for others, and the difference may be individual variation in GIP signaling.

When Trulicity is actually the better choice

Despite Zepbound's superior efficacy, Trulicity is the better choice in specific clinical scenarios:

1. Type 2 diabetes with insurance coverage and modest weight loss goals

If your insurance covers Trulicity, you have type 2 diabetes, and you'd be satisfied with 5 to 8% weight loss, Trulicity is the rational choice. It's effective, covered, and reaches maximum dose faster.

2. Patients with chronic diarrhea or IBS-D

Tirzepatide causes more diarrhea than dulaglutide (16.4% vs 8.6%). Patients with baseline diarrhea-predominant IBS or chronic diarrhea tolerate dulaglutide better. The constipation side effect of dulaglutide can actually be therapeutic in this population.

3. Faster titration preference

Patients who want to reach maximum efficacy in 4 weeks rather than 20 weeks prefer Trulicity. The trade-off is lower maximum efficacy, but some patients value speed over magnitude.

4. Needle anxiety

Trulicity's single-dose pen is slightly easier to use than Zepbound's autoinjector for patients with severe needle anxiety. Both are pre-filled and don't require manual injection, but Trulicity's pen hides the needle completely.

5. Cost sensitivity with diabetes

If paying out of pocket, compounded semaglutide is cheaper than compounded tirzepatide and more effective than dulaglutide. But if insurance covers Trulicity and won't cover anything else, Trulicity wins on cost.

The broader principle: Trulicity is the better choice when insurance coverage, tolerability, or titration speed outweighs the efficacy difference.

The decision framework: which medication for which patient

Use this framework to decide between Trulicity and Zepbound (or their compounded equivalents):

Step 1: Is type 2 diabetes the primary diagnosis?

• Yes, and A1C is the main goal → Either medication works; choose based on insurance coverage
• Yes, but weight loss is equally important → Zepbound or compounded tirzepatide
• No, weight loss only → Zepbound or compounded tirzepatide (Trulicity not FDA-approved for this)

Step 2: What is the weight loss goal?

• 5 to 10% body weight → Trulicity sufficient if diabetes is present
• 15 to 20% body weight → Zepbound or compounded tirzepatide required
• Maximum possible weight loss → Zepbound 15 mg or compounded tirzepatide

Step 3: What does insurance cover?

• Covers Trulicity for diabetes → Start there; switch if weight loss inadequate
• Covers Zepbound for obesity → Use Zepbound
• Covers neither → Compounded tirzepatide or compounded semaglutide based on budget

Step 4: Are there tolerability concerns?

• Chronic diarrhea or IBS-D → Trulicity preferred
• Chronic constipation → Zepbound preferred
• No baseline GI issues → Either medication

Step 5: How quickly do you need maximum effect?

• Need rapid A1C reduction (e.g., A1C >9%) → Trulicity reaches max dose faster
• Can tolerate 20-week titration → Zepbound delivers greater long-term effect

Step 6: If paying out of pocket, what's the budget?

• $300 to $450/month → Compounded tirzepatide
• $250 to $350/month → Compounded semaglutide (more effective than Trulicity, less than tirzepatide)
• $1,000+/month → Brand-name Trulicity or Zepbound

This framework eliminates 80% of the decision paralysis. The remaining 20% requires provider consultation about individual medical history.

Compounded options and the brand-name shortage context

As of April 2026, tirzepatide remains on the FDA drug shortage list, making compounded tirzepatide legal under Section 503A of the Federal Food, Drug, and Cosmetic Act. Dulaglutide is not on the shortage list, so compounded dulaglutide is not legally available through 503A compounding pharmacies.

This creates an asymmetry: patients can access compounded tirzepatide but not compounded dulaglutide. The practical result is that patients seeking a cost-effective GLP-1-only agonist choose compounded semaglutide (also on the shortage list) rather than compounded dulaglutide.

Compounded tirzepatide vs brand-name Zepbound

Compounded tirzepatide contains the same active ingredient as Zepbound but is not FDA-approved. It's prepared by state-licensed 503A compounding pharmacies in response to individual prescriptions. Differences include:

• Lower cost ($300 to $450/month vs $1,349/month)
• Requires manual injection with insulin syringes (not an autoinjector)
• May contain additional ingredients like B12 or L-carnitine
• No FDA review for safety, efficacy, or manufacturing consistency

The efficacy data for compounded tirzepatide comes from the same published trials as brand-name Zepbound because the active ingredient is identical. The difference is manufacturing oversight and delivery mechanism.

Patients using compounded tirzepatide through FormBlends follow the same titration schedule as brand-name Zepbound and report similar weight loss outcomes in aggregate. Individual results vary based on adherence, diet, and baseline metabolic factors.

FAQ

What is the main difference between Trulicity and Zepbound? Trulicity is a GLP-1-only receptor agonist; Zepbound is a dual GLP-1 and GIP receptor agonist. Zepbound produces 2.5 times more weight loss (21% vs 8.5% body weight) and greater A1C reduction (2.4% vs 1.5%) than Trulicity at maximum doses.

Which is better for weight loss, Trulicity or Zepbound? Zepbound is significantly more effective for weight loss. Clinical trials show 20.9% body weight loss with Zepbound 15 mg vs 4.7% with Trulicity 1.5 mg at comparable durations. Zepbound is FDA-approved for obesity; Trulicity is not.

Which is better for type 2 diabetes? Both are effective for type 2 diabetes. Zepbound produces greater A1C reductions (2.4% vs 1.5%) and gets more patients to target A1C under 7% (86% vs 61%). Trulicity is sufficient for patients with modest A1C goals and is often better covered by insurance for diabetes.

Do Trulicity and Zepbound have the same side effects? Nausea and vomiting rates are nearly identical (17-18%). Zepbound causes more diarrhea (16.4% vs 8.6%), while Trulicity causes more constipation (10.2% vs 6.1%). Both carry the same warnings for pancreatitis, gallbladder disease, and thyroid tumors.

Can I switch from Trulicity to Zepbound? Yes. Most providers recommend stopping Trulicity and starting Zepbound at the 2.5 mg dose one week later. Because both are once-weekly medications with similar half-lives, no washout period is needed. Discuss the switch with your provider to ensure appropriate dosing.

Is Zepbound just a stronger version of Trulicity? No. Zepbound contains a different active ingredient (tirzepatide vs dulaglutide) and activates two receptors instead of one. The GIP receptor activation creates synergistic effects beyond what a higher dose of Trulicity could achieve. They are mechanistically different medications.

Which costs more, Trulicity or Zepbound? Zepbound costs more at list price ($1,349/month vs $1,087/month), but insurance coverage patterns differ dramatically. Trulicity is usually covered for diabetes. Zepbound for weight loss is often not covered, forcing patients to pay out of pocket or use compounded tirzepatide.

How long does it take to see results with each medication? Trulicity reaches maximum dose in 4 weeks; most weight loss occurs in the first 12 to 16 weeks. Zepbound requires 20 to 24 weeks to reach maximum dose; weight loss continues through 72 weeks. A1C improvements appear within 4 to 8 weeks for both medications.

Can I use Trulicity for weight loss if I don't have diabetes? Trulicity is not FDA-approved for weight loss without diabetes. Most insurance plans won't cover it for obesity alone. Some providers prescribe it off-label, but Zepbound or compounded semaglutide are better choices for weight loss without diabetes.

Does Trulicity cause less nausea than Zepbound? No. Nausea rates are nearly identical: 17.1% for Trulicity vs 18.2% for Zepbound. The nausea is caused by slowed gastric emptying, which both medications produce. Nausea severity and duration are comparable between the two.

Which medication is easier to inject? Both are once-weekly subcutaneous injections. Trulicity uses a single-dose pen that hides the needle completely. Zepbound uses an autoinjector with a visible needle. Most patients find both easy to use after the first injection. Compounded versions require manual injection with insulin syringes.

Can I take Trulicity and Zepbound together? No. Both medications activate the GLP-1 receptor, so taking them together would cause overlapping effects and increase side effect risk without additional benefit. Combining GLP-1 medications is not recommended and is not supported by clinical evidence.

Will insurance cover Zepbound if I'm already on Trulicity? Usually not, unless you have inadequate response to Trulicity documented over 12 to 16 weeks. Insurance typically requires step therapy: try metformin, then a GLP-1 like Trulicity, then escalate to Zepbound only if prior treatments fail. Coverage for weight loss is inconsistent regardless of prior medications.

Is compounded tirzepatide as effective as brand-name Zepbound? Compounded tirzepatide contains the same active ingredient and produces similar weight loss outcomes in clinical practice. The difference is manufacturing oversight, delivery mechanism, and FDA approval status. Compounded medications are not FDA-approved and are prepared by state-licensed pharmacies.

What happens if I miss a dose of Trulicity or Zepbound? For both medications: if you miss a dose and it's been less than 3 days, take it as soon as you remember. If it's been more than 3 days, skip the missed dose and resume your regular schedule. Don't double up. Missing occasional doses reduces efficacy but doesn't cause withdrawal or rebound effects.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Frias JP et al. Efficacy and safety of dulaglutide 3.0 mg and 4.5 mg versus dulaglutide 1.5 mg in metformin-treated patients with type 2 diabetes in a randomized controlled trial (AWARD-11). Diabetes, Obesity and Metabolism. 2021.
3. Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
4. Nauck MA et al. Efficacy and safety of dulaglutide versus sitagliptin after 104 weeks in type 2 diabetes (AWARD-5). Lancet. 2014.
5. Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023.
6. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3). Lancet. 2021.
7. Samms RJ et al. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. Cell Metabolism. 2023.
8. Coskun T et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Nature Metabolism. 2024.
9. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
10. Davies M et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): gastric emptying substudy. Diabetes Care. 2023.
11. American College of Gastroenterology. Guidelines for the Diagnosis and Management of GERD. 2022.
12. FDA Drug Shortage Database. Tirzepatide injection shortage status. Accessed April 2026.
13. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
14. Eli Lilly and Company. Trulicity (dulaglutide) Prescribing Information. Updated 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Trulicity is a registered trademark of Eli Lilly and Company. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Wegovy and Ozempic are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.